Ms Emily Rigby
Australian Institute for Medical Cannabis Inc. & Cannatrek Medical Pty Ltd, Australia
Title: Medicinal Cannabis PTSD Study for Military Veterans & First Responders
Biography
Biography: Ms Emily Rigby
Abstract
The cannabis plant has been used for thousands of years to treat neurological indications. A majority of current users, source the plant and self-medicate. PTSD diagnosis results from an inability of sufferers to properly process traumatic events. There is a 600% increase in suicide risk among acute sufferers and many die with the condition. The negative impact is trans-generational and cost to community and country are enormous. The Australian Institute for Medical Cannabis (AIMC) believes one of the most at-risk groups are sufferers from PTSD. Medicinal Cannabis (MC) legislation recently introduced in Australia allows research and use of MC to treat wide range of diseases in humans. A number of at-risk groups have been identified in the community for clinical trials.
Current PTSD treatment regimes for military veterans claim over 80% success rates, although the suicide statistics tell another story. Around the world, PTSD related suicides among this group tend to heavily outnumber battlefield casualties. An estimated 8% of the population suffer PTSD symptoms. Although some research has been done with cannabis to treat PTSD, evidence of its efficacy is inconclusive. AIMC proposes a 12 month MC study involving diagnosed PTSD patients. The study aims to test the efficacy of various genetic of MC in the treatment of PTSD and correlate current patient use with reaction analytics from existing and new patient data bases. Our aim is to develop an alternative treatment of PTSD, that may promise a better quality of life to diagnosed PTSD patients and their families.